

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Nintedanib for previously treated advanced or metastatic NSCLC

Batch 32

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No potential equality issues were identified during the draft scope consultation. It was discussed at the scoping workshop that the pivotal trials for nintedanib included people whose disease had progressed following first-line, and did not include people whose disease progressed following maintenance therapy. This could be a potential equalities issue given maintenance therapy is now used in clinical practice for some patients following first-line induction therapy. The population in the scope is 'Adults with locally advanced or metastatic non-small cell lung cancer that has progressed following prior chemotherapy' and therefore would include this group. However, the expected marketing authorisation is not likely to include this subgroup of people and NICE technology appraisal guidance will only be issued in accordance with the marketing authorisation. As a result, this is not an equalities issue that can be addressed by the recommendations for this appraisal.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Given NICE technology appraisal guidance can only be issued in accordance with the marketing authorisation this is not considered an equalities issue that can be addressed by the Committee in this appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made to the draft scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders related to potential equality have been identified during the scoping process.

Approved by Associate Director (name): Helen Knight

Date: August 2014